ADIPOQ and breast cancer: In a pilot study performed in early-stage breast cancer patients, the short-term administration of rosiglitazone failed to reduce breast tumor proliferation, reduced insulin resistance, and increased serum adiponectin levels, which are considered breast cancer risk factors [45].